

REMARKS

Claims 2-7, 10, and 19 have been canceled, Claims 24-31 have been added. Support for the hybridization conditions set forth in new Claims 29-31 is found in the specification in Example 4. No new matter has been entered by these amendments. In view of the foregoing claim amendments and the arguments that follow, applicants submit that all of the pending claims are in condition for allowance.

Objection to Claims 1, 8-10 and 20-21 for Being Drawn to Non-Elected Products

Applicants submit that the Examiner's objection is moot in view of the foregoing claim amendments.

Rejection of Claim 10 Under 35 USC § 112, First Paragraph

Claim 10 has been canceled.

Rejection of Claim 10 Under 35 USC § 102(b)

Claim 10 has been canceled.

Rejection of Claims 1-2, 6-10, 18, and 20-21 Under 35 USC § 102(b) as Being Allegedly Anticipated by Davin et al. (*Anais da Academia Brasileira de Ciências* 67(3):363-378, 1995)

Claims 2, 6, 7, and 10 have been canceled. The Examiner characterizes the Davin et al. publication as teaching that a secoisolariciresinol dehydrogenase has been purified, and that cloning of this gene has been undertaken. In particular, the Examiner refers to the abstract of the Davin et al. publication.

As explained more fully below, applicants respectfully submit that the Davin et al. publication does not teach that a secoisolariciresinol dehydrogenase has been purified, or the cloning of this gene has been undertaken. The Davin et al. publication teaches that a (+)-pinoresinol/(+)-lariciresinol reductase has been purified and that cloning of this gene had been undertaken.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSSM
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

Lignans are a structurally diverse group of plant natural products that are made from various simple phenyl compounds called phenylpropanoids. The phenylpropanoids are modified and linked to form a wide range of oligomeric lignans, which, in turn, are linked to yield the complex lignin biopolymers.

The structurally diverse lignans can be classified according to the location of the linkage of the subunits from which they are constructed. Lignans are typically classified as one of the following linkage groups: 8-8', 8-1', 8-5', 8-0-4', 5-5', 3-0-4', 7-1', 8-7', 1-5', and 2-0-3'.

The 8-8' linked lignan pinoresinol, is a central intermediate in lignan metabolism. FIGURE 1, attached hereto as Attachment A, shows the biosynthesis of (+)-pinoresinol, and its conversion to some other important lignans. In particular, FIGURE 1 shows the conversion of (+)-pinoresinol to (+)-lariciresinol and then to (-)-secoisolariciresinol. Both of these reactions are catalyzed by the enzyme (+)-pinoresinol/(+)-lariciresinol reductase, which is the enzyme referred to in the abstract of the Davin et al. publication.

The present patent application is directed to secoisolariciresinol dehydrogenase which converts (-)-secoisolariciresinol to (-)-matairesinol as shown in FIGURE 1. The Davin et al. publication does not disclose an isolation, characterization, or cloning of secoisolariciresinol dehydrogenase.

Thus, applicants submit that the subject matter defined by the pending claims is neither anticipated, nor rendered obvious, by the teachings of the Davin et al. publication.

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

CONCLUSIONS

In view of the foregoing claim amendments and arguments, applicants respectfully submit that all of the pending claims are in condition for allowance. Reconsideration and favorable action are requested.

Respectfully submitted,


CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PC}



Barry F. McGurl
Registration No. 43,340
Direct Dial No. 206.695.1775

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to ~~Mail Stop~~ _____, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.


Date: 8/11/03



BFM:jlj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

FIGURE 1



CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC
1820 FIFTH AVENUE, S.
SUITE 2800
SEATTLE, WASHINGTON 98101
(206) 682-8100

Bank of America
100 OLIVE WAY, CASE
SEATTLE, WA 98101

150101
150101
AMOUNT \$410.00

DATE 08/08/2003

PAY Four Hundred Ten and 00/100 Dollars

TO THE DIRECTOR, U.S. PATENT AND TRADEMARK OFFICE
ORDER WASHINGTON, DC 20231
OR

150101 125000024 52023 051

CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC

PAGE 1
W-9: 150101
AMOUNT 410.00

DIRECTOR - U.S. PATE

INVOICE DATE
08/08/2003

CLIENT MATTER INVOICE NUMBER
WSUR 0016430 080803.13

- Response, Two Months Late Fee
DIRECTOR - U.S. PATENT AND
TRADEMARK OFFICE

File No.: WSUR-1-16430

Atty/Secy: BFM:jlj

Date: 8/11/03

Appln. No.: 09/673,918

Filed: 1/2/01

Applicant(s): Xia et al.

Title: RECOMBINANT SECOISOLARICIRENOL DEHYDROGENASE, AND METHODS OF USE

The following have been received in the U.S. Patent and Trademark Office on the date stamped hereon via first-class mail, with a signed Certificate of Mailing:

Check No. 150101 for \$410.00

Transmittal (2 pages) In duplicate

Amendment/Response (7 pages)

Attachment A (FIGURE 1)



Judy Jeppesen

From: Jennifer Davies
Sent: Wednesday, October 22, 2003 11:00 AM
To: Judy Jeppesen; Accounting
Subject: RE: Check 150101, \$410, dated 8/8/03

Cleared 8/21/03.

Jennifer Davies

-----Original Message-----

From: Judy Jeppesen
Sent: Wednesday, October 22, 2003 10:16 AM
To: Accounting
Subject: Check 150101, \$410, dated 8/8/03

Can you tell me when check no. 150101, for \$410, dated 8/8/03 was cashed? Thanks, Judy

Judith Jeppesen

Assisting Barry F. McGurl, Esq., Laura A. Cruz, Esq., and Jerald E. Nagae, Esq.
Christensen O'Connor Johnson Kindness^{PLLC}
1420 Fifth Avenue, Suite 2800
Seattle, WA 98101-2347 USA
Phone: 206-682-8100, ext. 1202; Fax: 206-224-0779;
E-mail: jeppesj@cojk.com; Web page: <http://www.cojk.com>

The information contained in this e-mail message may be privileged and is confidential information intended only for the use of the recipient named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, any use, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy the original message from your electronic files.